Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
Thea H WikenMarte Lie HøivikLydia C T BuerDavid J WarrenNils BolstadBjørn A MoumKaroline AnisdahlMilada C SmåstuenAsle Wilhelm MedhusPublished in: Scandinavian journal of gastroenterology (2023)
Nine out of ten patients still received SC treatment after 26 weeks. No change in disease activity occurred, and levels of serum VDZ increased. Although almost one fifth of patients experienced ISRs, a higher proportion favored SC administration at 26 weeks. This study demonstrates that SC maintenance treatment is a safe and feasible alternative to IV treatment.